2019 Shining Health Care Stars - PME, NAN, AVH

  • Dec 29, 2019 AEDT
  • Team Kalkine
2019 Shining Health Care Stars - PME, NAN, AVH

In a global study that compared the prices of a few of the most widely recognised and essential treatments, Australia ranked 40th in a group of 50 countries.

The key trends driving Australia’s health care sector in 2019 are investments in infrastructure, advancement in health care technology, patient experience, and ageing population.

Investments in infrastructure- According to a few media reports, it is estimated that by 2050 there would be 36 million people living in Australia. With an increasing number of residents coupled with an ageing population, it is projected that hospitals will become a priority for health care providers as well as for governments to continue supporting a healthy population.

In addition to infrastructure investments, significant advancements have been made in health care technology, while patient-centric care continues to be a key trend in health care. It has been observed that patients are embracing the flexibility that innovative technology brings to their care. Further, the ageing population brings with it several challenges with the upsurge of chronic diseases and an increasing requirement of serviceability.

In this article, we highlight three ASX listed health care stocks and their achievements in 2019.

Let us discuss PME, NAN, AVH-

Pro Medicus Limited (ASX: PME)

An ASX listed health care company, Pro Medicus Limited was founded in 1983 and is a leader in providing medical imaging IT services. The company’s wide range of radiology IT software and services are used by imaging centres, health care groups and hospitals at a global level. Pro Medicus also offers e-health solutions, RIS and PACS.

The company bought Visage Imaging in January 2009, which has now become a provider of best imaging solutions.

Financial year 2019 highlights- (Year ended 30 June 2019)

ü Pro Medicus generated revenue of $50.11 million in FY2019, up by 47.9%.

ü Cash reserves of the company for FY2019 were $32.32 million, a YoY increase of 28%.

ü Profit after tax of the company stood at $19.13 million, which was up by 91.9%.

ü The underlying NPAT of the company was $22.74 million, up by 83.1%.

ü The EBIT margins reached 51.6%.

Acquisition and partnership made in 2019-

In 2019, the company entered multiple partnerships by either signing new contracts/extensions or renewal of existing contracts-

Stock Performance

PME’s market capitalisation stands at around $2.44 billion, with approximately 103.95 million shares outstanding. On 27 December 2019, the PME stock closed at $23.520, in line with the previous day’s closing price. PME has generated positive returns of 108.83 per cent on year to date basis. The PME stock has a 52-week high and low price of $38.390 and $10.813, respectively.

Nanosonics Limited (ASX: NAN)

Sydney, Australia-headquartered health care player Nanosonics Limited was founded in 2001 and is an innovator in the prevention of infection through its unique, automated trophon® EPR high-level disinfection device. Trophon is a comprehensive solution for reducing the spread of health care acquired infections by decreasing the contamination between the patients. Nanosonics employs over 200 employees and has its offices in Europe, UK, Canada and North America. The company’s technology is available in many countries, including Australia, North America, Canada, the UK, Ireland, Germany, France, and Belgium among others.

Financial highlights 2019- (year ended 30 June 2019)

ü Nanosonics generated total revenue of approximately $84.3 million up by 39% as compared to the previous corresponding period (pcp).

ü Capital revenue reported at $32.8 million, which was up by 28%.

ü The operating expenses of the company reported at $49.2 million for FY2019.

ü The company reported a profit before tax of $16.8 million.

ü The cash and cash equivalents of the company was reported at $72.2 million.

Stock Performance

NAN’s market capitalisation stands at around $1.95 billion, with approximately 300.48 million shares outstanding. On 27 December 2019, the NAN stock closed at $6.520, an increase of 0.308 per cent. NAN has generated positive returns of 133.81 per cent on year to date basis. The NAN stock has a 52-week high and low price of $7.600 and $2.650, respectively.

AVITA Medical (ASX: AVH)

An ASX listed health care player, AVITA Medical is a company focused on regenerative treatment having a technology platform set for the unmet medical demands in chronic wounds, burns and aesthetics indications. The company’s patented technology offers regenerative properties-based new therapy and work by preparing a suspension known as REGENERATIVE EPIDERMAL SUSPENSION™ consisting of skin cells of patients which are necessary to rejuvenate natural healthy epidermis.

In 2019, the company achieved a decent growth. Some of the achievement from 2019 are discussed below-

ü Skin Regeneration Platform- The platform for regenerative medicine, designed by surgeons at the US Burn Centers, is an autologous cell harvesting device which uses the proprietary enzyme and buffers preparations for making of Spray-On Skin™ cells. This is AVITA’s first FDA approved product used in burn care for over twenty years.

ü RECELL market in the United States- In September 2018, the company received approval from FDA for RECELL. Post approval, RECELL showed remarkable growth in the US market with over half of the surgeons and burn centres trained in RECELL.

ü Secured place on the S&P/ASX 200 Index- According to an ASX announcement on 8 November 2019, AVITA Medical unveiled that it will be included in the S&P/ASX 200 index from 14 November 2019. In Australia, the S&P/ASX 200 Index is credited as the institutional investable standard and evaluates the performance of the top 200 companies based on the respective company’s market capitalisation on the ASX.

ü Nasdaq Listing- AVITA medical revealed that it has begun trading on Nasdaq Capital Market (Nasdaq) effective 1 October 2019 with the code “RCEL”.

Financial Highlights for the fiscal year 2019 (year ended 30 June 2019)-

ü AVITA medical generated total net revenue of $14.723 million for FY2019.

ü The global sales revenue was $7.705 million.

ü AVITA medical had $134.5 million in cash as of 22 November 2019.

ü The company’s cash & cash equivalents were $28.983 million.

ü EBITDA of the company stood at $34.962 million.

Stock Performance

AVH’s market capitalisation stands at around $1.32 billion, with approximately 2.12 billion shares outstanding. On 27 December 2019, the AVH stock closed at $0.640, an increase of 2.4 per cent. AVH has generated positive returns of 691.14 per cent on year to date basis. The AVH stock has a 52-week high and low price of $0.740 and $0.077, respectively.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

ü Pro Medicus generated revenue of $50.11 million in FY2019, up by 47.9%.

ü Cash reserves of the company for FY2019 were $32.32 million, a YoY increase of 28%.

ü Profit after tax of the company stood at $19.13 million, which was up by 91.9%.

ü The underlying NPAT of the company was $22.74 million, up by 83.1%.

ü The EBIT margins reached 51.6%.

Acquisition and partnership made in 2019-

In 2019, the company entered multiple partnerships by either signing new contracts/extensions or renewal of existing contracts-

Stock Performance

PME’s market capitalisation stands at around $2.44 billion, with approximately 103.95 million shares outstanding. On 27 December 2019, the PME stock closed at $23.520, in line with the previous day’s closing price. PME has generated positive returns of 108.83 per cent on year to date basis. The PME stock has a 52-week high and low price of $38.390 and $10.813, respectively.

Nanosonics Limited (ASX: NAN)

Sydney, Australia-headquartered health care player Nanosonics Limited was founded in 2001 and is an innovator in the prevention of infection through its unique, automated trophon® EPR high-level disinfection device. Trophon is a comprehensive solution for reducing the spread of health care acquired infections by decreasing the contamination between the patients. Nanosonics employs over 200 employees and has its offices in Europe, UK, Canada and North America. The company’s technology is available in many countries, including Australia, North America, Canada, the UK, Ireland, Germany, France, and Belgium among others.

Financial highlights 2019- (year ended 30 June 2019)

ü Nanosonics generated total revenue of approximately $84.3 million up by 39% as compared to the previous corresponding period (pcp).

ü Capital revenue reported at $32.8 million, which was up by 28%.

ü The operating expenses of the company reported at $49.2 million for FY2019.

ü The company reported a profit before tax of $16.8 million.

ü The cash and cash equivalents of the company was reported at $72.2 million.

Stock Performance

NAN’s market capitalisation stands at around $1.95 billion, with approximately 300.48 million shares outstanding. On 27 December 2019, the NAN stock closed at $6.520, an increase of 0.308 per cent. NAN has generated positive returns of 133.81 per cent on year to date basis. The NAN stock has a 52-week high and low price of $7.600 and $2.650, respectively.

AVITA Medical (ASX: AVH)

An ASX listed health care player, AVITA Medical is a company focused on regenerative treatment having a technology platform set for the unmet medical demands in chronic wounds, burns and aesthetics indications. The company’s patented technology offers regenerative properties-based new therapy and work by preparing a suspension known as REGENERATIVE EPIDERMAL SUSPENSION™ consisting of skin cells of patients which are necessary to rejuvenate natural healthy epidermis.

In 2019, the company achieved a decent growth. Some of the achievement from 2019 are discussed below-

ü Skin Regeneration Platform- The platform for regenerative medicine, designed by surgeons at the US Burn Centers, is an autologous cell harvesting device which uses the proprietary enzyme and buffers preparations for making of Spray-On Skin™ cells. This is AVITA’s first FDA approved product used in burn care for over twenty years.

ü RECELL market in the United States- In September 2018, the company received approval from FDA for RECELL. Post approval, RECELL showed remarkable growth in the US market with over half of the surgeons and burn centres trained in RECELL.

ü Secured place on the S&P/ASX 200 Index- According to an ASX announcement on 8 November 2019, AVITA Medical unveiled that it will be included in the S&P/ASX 200 index from 14 November 2019. In Australia, the S&P/ASX 200 Index is credited as the institutional investable standard and evaluates the performance of the top 200 companies based on the respective company’s market capitalisation on the ASX.

ü Nasdaq Listing- AVITA medical revealed that it has begun trading on Nasdaq Capital Market (Nasdaq) effective 1 October 2019 with the code “RCEL”.

Financial Highlights for the fiscal year 2019 (year ended 30 June 2019)-

ü AVITA medical generated total net revenue of $14.723 million for FY2019.

ü The global sales revenue was $7.705 million.

ü AVITA medical had $134.5 million in cash as of 22 November 2019.

ü The company’s cash & cash equivalents were $28.983 million.

ü EBITDA of the company stood at $34.962 million.

Stock Performance

AVH’s market capitalisation stands at around $1.32 billion, with approximately 2.12 billion shares outstanding. On 27 December 2019, the AVH stock closed at $0.640, an increase of 2.4 per cent. AVH has generated positive returns of 691.14 per cent on year to date basis. The AVH stock has a 52-week high and low price of $0.740 and $0.077, respectively.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

-->

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK